Baiya Phytopharm Co., Ltd.

What Baiya Phytopharm Co., Ltd. does

Baiya Phytopharm Co., Ltd. is a privately held, clinical-stage biopharmaceutical company founded in 2018 and headquartered in Bangkok, Thailand. The company operates with a headcount of 51-100 employees, consistent with a development-stage biopharma building out R&D, clinical, and regulatory functions. Its core activity centers on advancing pharmaceutical candidates through clinical development, though no specific drug candidates, therapeutic areas, modalities, or pipeline assets are documented in the available data.

The company's business model is consistent with a pre-commercial biopharma: revenue is not yet generated from product sales, and operations are funded by equity capital. The input documents a single funding event in January 2023 involving CU ENTERPRISE CO., LTD. as an investor, with the round amount undisclosed (recorded as $0). No additional funding rounds, partnerships, licensing agreements, or grant income are recorded. The company website (baiyaphytopharm.com) was not accessible as a data source (loading/verification page only), and no management team, product details, technology stack, or geographic operating footprint beyond Thailand were available in the input.

Given the absence of disclosed pipeline assets, clinical trial milestones, regulatory submissions, or commercial partnerships in the input, Baiya Phytopharm should be treated as a data-thin clinical-stage company. The available signals support only a baseline description: a Bangkok-based, private, pre-revenue biopharmaceutical entity in operation since 2018, with a single disclosed capital event in 2023 and no documented commercial or scientific milestones.

Name

Baiya Phytopharm Co., Ltd.

Website

https://baiyaphytopharm.com

Company type

Private

Founded year

2018

Headcount range

11–50 employees

Short description

Baiya Phytopharm Co., Ltd. is a privately held, clinical-stage biopharmaceutical company founded in 2018 and headquartered in Bangkok, Thailand, with 51-100 employees focused on advancing pharmaceutical candidates through clinical development.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts) (AFAJAKAD)

Keywords

• Plant-derived pharmaceuticals
• Clinical-stage biopharma
• Botanical therapeutics
• Phytopharmaceutical development
• Biopharmaceutical R&D

Headquarters

HQ city

Bangkok

HQ country

Thailand

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Baiya Phytopharm Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing plant-derived (phytopharmaceutical) therapeutic candidates. The company conducts research and development activities aimed at advancing botanical-origin drug candidates through clinical stages for eventual pharmaceutical application.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights3 records

Direct peers

• Indena: Italian company specializing in botanical extracts and active pharmaceutical ingredients derived from plants. Directly comparable as a player developing standardized plant-derived compounds for pharmaceutical and nutraceutical applications.
• Sabinsa Corporation: US-headquartered (with India operations) company developing and manufacturing standardized botanical extracts for pharmaceutical and nutraceutical use. Comparable as a developer of clinically validated plant-derived compounds with global commercialization.
• Bioland Co., Ltd. Korean company manufacturing botanical and herbal extracts for pharmaceutical, nutraceutical, and cosmetic applications. Comparable as an Asia-based developer of standardized plant-derived pharmaceutical ingredients.
• Hutchison China MediTech (Chi-Med): Asia-based clinical-stage biopharma with a strong focus on botanical-derived and natural-product-based therapeutics. Most directly comparable in combining plant-derived chemistry with modern drug-development infrastructure.

Broad incumbents

• Martin Bauer Group: German-based global supplier of botanical extracts and tea/herbal ingredients used in pharmaceutical and functional food applications. Comparable as an established incumbent in plant-derived pharmaceutical raw materials.
• Natureceuticals / Naturex (Givaudan): Large global ingredient company with significant botanical extract capabilities. Comparable as a broader incumbent in the plant-derived active ingredient space, though operating at much larger scale across multiple end markets.

Emerging players

• AstaReal (Fuji Chemical Industries): Developer and manufacturer of natural/botanical-derived active ingredients for pharmaceutical and nutraceutical applications. Comparable as a smaller specialty player using natural-source extraction and standardization for therapeutic applications.
• PhytoHealth Corporation: Taiwan-based emerging pharma developing botanical and plant-derived drug products. Comparable as a smaller, plant-focused biopharma in the Asia-Pacific region pursuing regulated therapeutic products.

Regional players

• Chengdu Di'ao Pharmaceutical Group: China-based pharmaceutical manufacturer with significant botanical/traditional Chinese medicine-based drug portfolio. Comparable as an Asia-based operator combining traditional botanical medicine with modern pharmaceutical manufacturing.
• Government Pharmaceutical Organization (GPO, Thailand): Thai state-owned pharmaceutical manufacturer producing a wide range of medicines including traditional/herbal formulations. Comparable as a Thailand-based operator in botanical pharmaceuticals with both local manufacturing and clinical expertise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/baiyaphytopharm

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baiya Phytopharm Co., Ltd.